Attorney Docket No.: 10576.204-US PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al.

Confirmation No: 1316

Serial No.: 10/593,798

Group Art Unit: 1638

Filed: September 20, 2006

Examiner: TBA

For: Mutated Prokaryotic Cells with High Secretion-Levels

### REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This application was filed on September 20, 2006 as a national phase application of PCT/DK2005/000236. As indicated in the Application Data Sheet, the Preliminary Amendment dated September 20, 2006, and a copy of the attached PCT application cover sheet, the subject application is a US national phase of PCT/DK2005/000236 and claims priority or the benefit of Danish Application No. PA 2004 00582 filed on April 7, 2004 and U.S. provisional application no. 60/562,396 filed on April 14, 2004. Furthermore, the Declaration and Power of Attorney which was signed by the inventors appoints the practitioners at Customer Number 25908 as their attorneys.

The filing receipt mailed January 27, 2009 contains the following errors in the domestic and foreign priority section:

- 1. The PCT application incorrectly reads PCT/<u>US</u>05/00236 dated 01/05/2005 instead of the correct PCT/<u>DK</u>2005/00236 having an international filing date of 07 April 2005;
  - 2. the U.S. provisional application is omitted; and
  - 3. the foreign priority application is omitted.

Applicants therefore request the issuance of a corrected filing receipt with complete domestic and foreign priority data.

Applicants submit that the error was the fault of the USPTO and therefore no fee is due.

Respectfully submitted,

Date: January 30, 2009

/Michael W. Krenicky, Reg. # 45411/
Michael W. Krenicky, Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 20 October 2005 (20.10.2005)

PCT

## (10) International Publication Number WO 2005/098003 A1

- (51) International Patent Classification7: C12N 15/75, 1/21
- (21) International Application Number:

PCT/DK2005/000236

(22) International Filing Date:

7 April 2005 (07.04.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2004 00582

7 April 2004 (07.04.2004) DK

- (71) Applicant (for all designated States except US): NOVOZYMES A/S [DK/DK]; Krogshøjvej 36, DK-2880 Bagsværd (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): NIELSEN, Allan Kent [DK/DK]; Rolf Krakes Allé 19, DK-2860 Søborg (DK). RASMUSSEN, Michael Dolberg [DK/DK]; Syvhøjvænge 151, DK-2625 Vallensbæk (DK).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUTATED PROKARYOTIC CELLS WITH HIGH SECRETION-LEVELS

(57) Abstract: A mutated prokaryotic cell, which secretes higher amounts of at least one heterologous polypeptide of interest and which has a reduced expression-level of YusZ or YusX, or homologues thereof, when compared with an otherwise isogenic but non-mutated cell, and methods for constructing and using such a cell in the production of polypeptides.